{"gene":"ESR1","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":2003,"finding":"ERα and ERβ form functional heterodimers when coexpressed, and ERβ exhibits an inhibitory action on ERα-mediated gene expression; both receptors colocalize in the same discrete nuclear clusters upon ligand activation, with cluster formation requiring at least the latter part of AF-1, the DNA-binding domain, nuclear matrix binding domain, and AF-2/ligand-binding domain of ERα.","method":"Live-cell imaging with GFP-tagged fusion proteins, deletion mutant analysis, colocalization with hyperacetylated histone H4 and Brg-1 (chromatin remodeling complex component)","journal":"Molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — live-cell imaging with deletion mutants and functional colocalization markers in single study, single lab","pmids":["12351687"],"is_preprint":false},{"year":2004,"finding":"ERα receives the estrogen proliferation signal in mammary epithelial cells and initiates DNA synthesis, then is lost from the nucleus; ERβ facilitates the return of ERα to the nucleus and restores responsiveness to estradiol. Both ERα and ERβ can independently mediate estradiol-induced proliferation.","method":"BrdUrd incorporation assay in WT and ERβ-knockout mice treated with E2, tamoxifen, or ERβ-specific agonist; immunofluorescence with specific antibodies for ERα and ERβ localization","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic KO model with orthogonal methods (BrdU, immunofluorescence, multiple ligand conditions), replicated across genotypes","pmids":["14762170"],"is_preprint":false},{"year":2009,"finding":"ERα directly binds to the estrogen-responsive element (ERE) DNA motif to regulate a distinct set of uterine genes; loss of ERα DNA-binding activity (KIKO knock-in mouse) reveals that 38% of wild-type E2-regulated transcripts are also regulated via non-ERE tethered mechanisms, and an entirely unique set of 1438 transcripts is regulated only in the KIKO context. Canonical pathways including Jak/Stat are regulated similarly by ERE and non-ERE pathways, while Wnt/β-catenin pathway members differ.","method":"In vivo knock-in mouse model (KIKO) lacking ERα DNA-binding function; microarray gene expression profiling; comparison of WT, KIKO, and αERKO genotypes","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic knock-in with loss-of-function and genome-wide expression profiling across three genotypes","pmids":["19812388"],"is_preprint":false},{"year":2011,"finding":"ERα monoubiquitination is required for E2-induced ERα phosphorylation at Ser118, transcriptional activity, extranuclear AKT activation, cyclin D1 promoter activation, and cell proliferation; mutation of ERα monoubiquitination sites also disrupts E2-induced ERα association with IGF-1R.","method":"Site-directed mutagenesis of ERα monoubiquitination sites; cell proliferation assays; western blotting for phospho-Ser118, AKT activation; cyclin D1 promoter reporter assays; co-immunoprecipitation for IGF-1R interaction","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — mutagenesis combined with multiple functional readouts (signaling, transcription, proliferation) in single lab","pmids":["21356307"],"is_preprint":false},{"year":2013,"finding":"ERα (ESR1) overexpression in ER-negative Hep3B cells induces apoptosis via a ligand-dependent interaction with SP1 protein; the ERα-SP1 complex binds proximal and distal SP1 sites in the TNFα gene promoter, activating TNFα expression and downstream caspase-3 activation. Deletion of SP1 binding sites in the TNFα promoter abolished ERα-mediated promoter activity.","method":"DNA fragmentation assay; flow cytometry; western blotting for active caspase-3 and TNFα; co-immunoprecipitation of ERα and SP1; TNFα promoter reporter assays with SP1-site deletions; mithramycin (SP1 inhibitor) treatment","journal":"Journal of molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus promoter deletion experiments and pharmacological validation, single lab","pmids":["23733894"],"is_preprint":false},{"year":2015,"finding":"ESR1 somatic mutations clustered in the ligand-binding domain (LBD) confer ligand-independent ER transcriptional activity in metastatic breast cancer; these gain-of-function mutations (e.g., Y537S, D538G) promote estrogen-independent tumor growth and confer partial to full resistance to endocrine therapies including aromatase inhibitors and fulvestrant.","method":"Characterization of ESR1 mutations from >900 patients; in vitro functional assays for constitutive activity; in vivo xenograft models; comparison of sensitivity to ER antagonists including fulvestrant and AZD9496","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 2 / Strong — large clinical dataset combined with in vitro functional assays and in vivo xenograft models, replicated across multiple mutation variants","pmids":["27986707"],"is_preprint":false},{"year":2017,"finding":"ZEB1 represses ESR1 transcription by forming a ZEB1/DNMT3B/HDAC1 complex on the ESR1 promoter, leading to DNA hypermethylation and silencing of ERα; siRNA depletion of ZEB1 causes ESR1 promoter demethylation and restores ERα expression and antiestrogen sensitivity.","method":"Chromatin immunoprecipitation (ChIP); co-immunoprecipitation of ZEB1/DNMT3B/HDAC1 complex; siRNA knockdown; bisulfite sequencing; reporter assays; nude mouse xenograft model","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (ChIP, Co-IP, siRNA, bisulfite sequencing, in vivo xenograft) in single study","pmids":["28383555"],"is_preprint":false},{"year":2018,"finding":"ESR1 LBD mutations exhibit both ligand-independent functions that mimic estradiol-bound wild-type ER and allele-specific neomorphic (neomorphic/gain-of-function) chromatin recruitment properties that promote a pro-metastatic transcriptional program; genome-wide ER binding site analysis identified mutant ER-unique recruitment sites mediating allele-specific transcriptional programs.","method":"ChIP-seq for genome-wide ER binding; genetic screens for essential genes; transcriptional network analysis in breast cancer models with clinically relevant ER mutations","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide ChIP-seq combined with genetic screens, multiple cell models, rigorous controls","pmids":["29438694"],"is_preprint":false},{"year":2018,"finding":"ESR1 activation in adipocytes increases nuclear SP1 protein content, the SP1/ESR1 complex formation, and SP1 binding to the Slc2a4 gene promoter, resulting in increased Slc2a4/GLUT4 expression; this ESR1/SP1 cooperative mechanism is specific to ESR1 (not ESR2) and is demonstrated via immunoprecipitation of SP1/ESR1 complex and EMSA.","method":"Western blotting; immunoprecipitation of SP1/ESR1 complex; EMSA (electrophoretic mobility shift assay) for SP1 binding to Slc2a4 promoter; ESR1 agonist (PPT) and antagonist; siRNA knockdown","journal":"International journal of medical sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP and EMSA with orthogonal agonist/antagonist and siRNA controls, single lab","pmids":["30275758"],"is_preprint":false},{"year":2019,"finding":"Estradiol stimulates adipogenesis and Slc2a4/GLUT4 expression via an ESR1-dependent, CEBPA-mediated pathway; ESR1 silencing abrogates E2-induced nuclear CEBPA content, Slc2a4/GLUT4 expression, and GLUT4 translocation to the cell membrane.","method":"siRNA-mediated Esr1 silencing in 3T3-L1 adipocytes; western blotting; RT-qPCR; GLUT4 translocation assay","journal":"Molecular and cellular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA loss-of-function with multiple molecular readouts (protein content, mRNA, translocation), single lab","pmids":["31100494"],"is_preprint":false},{"year":2020,"finding":"RON kinase is hyperactivated in ESR1 Y537S mutant breast cancer cells and interacts with IGF-1R; RON/PI3K hyperactivity is regulated by mutant ER (reduced by endocrine therapies) and RON inhibition combined with endocrine therapy decreases organoid growth and reduces metastasis in an ESR1 Y537S PDX model.","method":"Proteomic kinome analysis; phospho-immunoblot; pharmacological and genetic inhibition of RON and IGF-1R; organoid growth assays; in vivo PDX metastatic model","journal":"British journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — kinome-wide screen plus genetic/pharmacological validation and in vivo PDX model, single lab","pmids":["33257837"],"is_preprint":false},{"year":2021,"finding":"ESR1 ChIP-seq in human hepatocytes and liver tissue identifies both ligand-dependent and ligand-independent (unliganded) ESR1 genomic binding sites with distinct genomic localization, pathway enrichment, and cofactor co-localization patterns; ligand-free ESR1 shows co-enrichment with ZNF143 and regulates CYP genes involved in drug metabolism.","method":"ChIP-seq in human liver samples and hepatocytes with/without 17β-estradiol; pathway enrichment analysis; cofactor co-localization analysis","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genome-wide ChIP-seq in primary human tissue, single study, no mutagenesis validation","pmids":["33540646"],"is_preprint":false},{"year":2022,"finding":"ESR1 hotspot mutations (Y537S, D538G) reprogram the ER cistrome via de novo FOXA1-driven chromatin remodeling and secondary transcriptional regulation; these mutations alter desmosome/gap junction genes and the TIMP3/MMP axis, functionally enhancing cell-cell contacts while decreasing cell-extracellular matrix adhesion, thereby promoting metastatic CTC cluster formation.","method":"Genome-edited ESR1 mutant cell models; transcriptomic and cistrome profiling; in vivo CTC cluster analysis; five independent breast cancer cohorts; Wnt/ER co-targeting experiments","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-edited models with cistrome/transcriptome profiling, multiple in vivo and in vitro readouts, and five clinical cohorts","pmids":["35078818"],"is_preprint":false},{"year":2022,"finding":"ESR1 mutant cells show induction of basal cytokeratins (BCKs) independent of ER binding, associated with chromatin reprogramming centered on a progesterone receptor-orchestrated insulated neighborhood; ESR1 mutant tumors also show elevated S100A8/S100A9 immune mediators via tumor-stroma paracrine crosstalk.","method":"Genome-edited ESR1 mutant cell models; ATAC-seq/ChIP-seq for chromatin reprogramming; single-cell RNA-seq from metastatic tumors; analysis of clinical samples","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-edited models combined with chromatin profiling (ATAC-seq/ChIP-seq), single-cell RNA-seq, and clinical validation","pmids":["35440136"],"is_preprint":false},{"year":2022,"finding":"TRIM4 E3 ligase catalyzes K48-linked polyubiquitination of SET at K150 and K172, promoting SET proteasomal degradation; loss of SET releases p53 and PP2A, which in turn promote ESR1 gene transcription and mRNA stability, thereby enhancing ERα expression and tamoxifen sensitivity.","method":"In vitro and in vivo ubiquitination assays; co-immunoprecipitation of TRIM4-SET (mapping to RING/B-box and SET C-terminus); domain mapping; western blotting; siRNA/overexpression experiments","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP domain mapping plus ubiquitination assay with multiple functional readouts, single lab","pmids":["35843886"],"is_preprint":false},{"year":2023,"finding":"Esr1-expressing (Esr1+) neurons in the lateral hypothalamic area (LHA) projecting to the lateral habenula (LHb) induce aversion and a behaviorally persistent aversive state upon repeated optogenetic activation; these neurons show sex-specific shifts in intrinsic bursting properties following unpredictable mild shocks in female mice, associated with stress sensitivity.","method":"Patch-seq multimodal classification; optogenetic stimulation; large-scale neural recordings; behavioral assays; electrophysiology","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — Patch-seq guided classification with optogenetic functional validation, large-scale recordings, and behavioral assays in defined Esr1+ cell population","pmids":["37349481"],"is_preprint":false},{"year":2024,"finding":"ESR1 F404 residue contributes to fulvestrant binding to ERα through a pi-stacking bond; acquired F404L/I/V mutations (in cis with activating mutations) disrupt this bond, causing overt resistance to fulvestrant but not to oral ERα degraders; compound mutations D538G+F404L and E380Q+F404L confer fulvestrant resistance in vitro.","method":"In silico structural modeling of F404-fulvestrant pi-stacking; in vitro cell line models with single and compound ESR1 mutations; sequencing of baseline and end-of-treatment ctDNA from clinical trial (PlasmaMATCH); pharmacological testing with oral ERα degraders","journal":"Cancer discovery","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — structural modeling with in vitro functional validation and clinical ctDNA sequencing, single study","pmids":["37982575"],"is_preprint":false},{"year":2009,"finding":"ERα suppresses expression of its variant ERα36 in an estrogen-independent manner by acting on the ERα36 promoter; ERα36 itself can release this suppression.","method":"Promoter cloning; transient co-transfection reporter assays; transcription initiation site mapping","journal":"FEBS letters","confidence":"Low","confidence_rationale":"Tier 3 / Weak — reporter assay only, single lab, no endogenous ChIP confirmation","pmids":["19328202"],"is_preprint":false},{"year":2008,"finding":"ERα activation (via estradiol or ESR1 agonist PPT) increases pancreatic beta-cell insulin content, insulin gene expression, and insulin release through ERK1/2 signaling; this effect is absent in ERα-knockout mice and is mimicked by bisphenol-A.","method":"ERα and ERβ agonists; ERαKO and ERβKO mouse models; ERK1/2 pathway inhibition; gene expression analysis","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO models combined with pharmacological agonist/antagonist approach and kinase pathway analysis, single lab","pmids":["18446233"],"is_preprint":false},{"year":2017,"finding":"ESR1 (ERα) activation by E2 induces binding of HIF1A to the VEGFA gene promoter in adipocytes, promoting VEGFA expression; ESR1-selective agonist (PPT) mimics this effect, while ESR1 siRNA knockdown decreases VEGFA and prevents E2-mediated modulation; ESR1 total body knockout female mice show lower VEGFA in adipose tissue.","method":"ChIP for HIF1A binding to VEGFA promoter; siRNA knockdown of ESR1; ESR1 agonist/antagonist treatment in 3T3-L1 cells; ESR1 total body knockout mice","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus siRNA knockdown plus in vivo KO model, single lab","pmids":["29196658"],"is_preprint":false},{"year":2012,"finding":"δEF1 represses ERα transcription by binding to the E2-box on the ERα promoter, an effect induced by E2 via ERα-dependent PI3K or NF-κB pathway; elevated δEF1 reduces ERα levels and confers tamoxifen resistance, while δEF1 depletion restores ERα expression and tamoxifen sensitivity.","method":"Luciferase reporter assays with E2-box promoter constructs; ChIP for δEF1 binding; siRNA knockdown; overexpression; western blotting","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter binding by ChIP, siRNA loss-of-function and overexpression with tamoxifen sensitivity readout, single lab","pmids":["23285017"],"is_preprint":false}],"current_model":"ESR1/ERα is a ligand-regulated nuclear transcription factor that binds estrogen response elements (EREs) directly or tethers to other transcription factors (e.g., SP1, AP1) at non-ERE sites to regulate target gene expression; its activity is modulated by post-translational modifications including monoubiquitination (required for Ser118 phosphorylation, AKT activation, and proliferation) and polyubiquitination via E3 ligases; somatic gain-of-function mutations in the ligand-binding domain (hotspots Y537S, D538G, etc.) confer ligand-independent constitutive activity, allele-specific neomorphic chromatin recruitment via FOXA1-driven reprogramming, enhanced metastatic adhesion/migration phenotypes, and resistance to aromatase inhibitors and fulvestrant; ERα expression is epigenetically silenced by ZEB1/DNMT3B/HDAC1-mediated promoter hypermethylation; Esr1+ neurons in the lateral hypothalamus signal aversion through projections to the lateral habenula."},"narrative":{"mechanistic_narrative":"ESR1 encodes ERα, a ligand-regulated nuclear transcription factor that controls estrogen-driven gene programs by either binding estrogen response elements (EREs) directly or tethering to other transcription factors at non-ERE sites; in vivo loss of its DNA-binding function shows that a substantial fraction of estradiol-regulated transcripts are governed through tethered, non-ERE mechanisms [PMID:19812388]. ERα can heterodimerize with ERβ, which restrains ERα-mediated transcription, and both receptors co-cluster in discrete ligand-induced nuclear foci [PMID:12351687]; both can independently transduce the estradiol proliferative signal in mammary epithelium [PMID:14762170]. A recurrent mechanistic theme is cooperative DNA binding with SP1: the ligand-dependent ERα–SP1 complex activates the TNFα promoter to drive caspase-3–dependent apoptosis in one context [PMID:23733894] and the Slc2a4/GLUT4 promoter to promote glucose-transporter expression in adipocytes [PMID:30275758]. ERα activity is gated by post-translational modification — monoubiquitination is required for E2-induced Ser118 phosphorylation, extranuclear AKT activation, cyclin D1 promoter activation, IGF-1R association, and proliferation [PMID:21356307]. ESR1 expression is itself epigenetically silenced through a ZEB1/DNMT3B/HDAC1 complex that hypermethylates the ESR1 promoter, and relieving this silencing restores antiestrogen sensitivity [PMID:28383555]. In metastatic breast cancer, somatic ligand-binding-domain hotspot mutations (Y537S, D538G) confer constitutive ligand-independent activity and endocrine-therapy resistance [PMID:27986707]; these alleles drive FOXA1-dependent cistrome reprogramming and neomorphic transcriptional programs that remodel cell adhesion and promote metastasis [PMID:29438694, PMID:35078818], and additional acquired mutations at residue F404 disrupt fulvestrant pi-stacking to cause selective drug resistance [PMID:37982575]. Beyond its transcriptional roles, Esr1-expressing neurons in the lateral hypothalamus signal aversion via projections to the lateral habenula [PMID:37349481].","teleology":[{"year":2003,"claim":"Established that ERα does not act alone but forms functional heterodimers with ERβ that modulate its transcriptional output and co-organize into defined nuclear chromatin foci.","evidence":"Live-cell imaging of GFP-tagged receptors with deletion mutants and colocalization with chromatin-remodeling markers","pmids":["12351687"],"confidence":"Medium","gaps":["Endogenous heterodimer occupancy at native target genes not mapped","Mechanism of ERβ inhibition of ERα not resolved"]},{"year":2004,"claim":"Resolved whether ERα and ERβ have distinct roles in estrogen-driven proliferation, showing ERα initiates the proliferative signal while ERβ governs ERα nuclear recycling and responsiveness.","evidence":"BrdU incorporation and immunofluorescence in WT and ERβ-knockout mice under multiple ligand conditions","pmids":["14762170"],"confidence":"High","gaps":["Molecular basis of ERα nuclear loss/return unknown","Target genes mediating proliferation not identified"]},{"year":2009,"claim":"Separated direct ERE-driven transcription from tethered non-ERE regulation in vivo, quantifying that a large fraction of estradiol-regulated genes use DNA-binding-independent mechanisms.","evidence":"KIKO DNA-binding-deficient knock-in mouse with genome-wide expression profiling across three genotypes","pmids":["19812388"],"confidence":"High","gaps":["Identity of tethering transcription factors at non-ERE sites not enumerated","Tissue specificity beyond uterus unaddressed"]},{"year":2011,"claim":"Defined monoubiquitination as a required upstream switch coupling ERα to Ser118 phosphorylation, extranuclear AKT signaling, IGF-1R association, and proliferation.","evidence":"Site-directed mutagenesis of ubiquitination sites with signaling, reporter, Co-IP, and proliferation readouts","pmids":["21356307"],"confidence":"Medium","gaps":["E3 ligase mediating monoubiquitination not identified","Single-lab functional readouts"]},{"year":2013,"claim":"Demonstrated ERα can cooperate with SP1 to drive a pro-apoptotic transcriptional program, broadening ERα function beyond proliferation.","evidence":"Co-IP, TNFα promoter reporter with SP1-site deletions, and SP1-inhibitor treatment in Hep3B cells","pmids":["23733894"],"confidence":"Medium","gaps":["Context-dependence (overexpression in ER-negative cells) limits generalization","Endogenous relevance not shown"]},{"year":2015,"claim":"Identified ligand-binding-domain hotspot mutations as the mechanistic basis of acquired endocrine resistance via constitutive ligand-independent ERα activity.","evidence":"Mutation characterization across >900 patients with in vitro constitutive-activity assays and xenograft antagonist-sensitivity testing","pmids":["27986707"],"confidence":"High","gaps":["Allele-specific downstream programs not yet resolved at this stage","Structural basis of constitutive activity not detailed"]},{"year":2017,"claim":"Established a transcriptional/epigenetic silencing mechanism controlling ESR1 expression itself through a ZEB1/DNMT3B/HDAC1 promoter complex linked to antiestrogen sensitivity.","evidence":"ChIP, Co-IP of the repressor complex, siRNA, bisulfite sequencing, and xenograft assays","pmids":["28383555"],"confidence":"High","gaps":["Upstream signals activating ZEB1 in this context not defined","Reversibility in patients not tested"]},{"year":2018,"claim":"Showed mutant ERα acquires neomorphic, allele-specific chromatin recruitment driving pro-metastatic transcription rather than merely mimicking liganded receptor.","evidence":"ChIP-seq cistrome mapping and genetic screens across breast cancer models with clinical mutations","pmids":["29438694"],"confidence":"High","gaps":["Pioneer factor driving neomorphic recruitment not yet pinpointed in this study","Therapeutic targeting of neomorphic sites unaddressed"]},{"year":2022,"claim":"Mechanistically linked hotspot mutations to FOXA1-driven cistrome reprogramming that remodels adhesion gene programs to promote circulating tumor cell cluster formation and metastasis.","evidence":"Genome-edited mutant models with cistrome/transcriptome profiling, in vivo CTC analysis, and five clinical cohorts","pmids":["35078818"],"confidence":"High","gaps":["How FOXA1 is redirected by LBD mutations remains mechanistically incomplete","Generalizability across mutation alleles partially explored"]},{"year":2022,"claim":"Extended mutant-ERα reprogramming to ER-binding-independent outputs, including basal cytokeratin induction via a progesterone-receptor-orchestrated insulated neighborhood and paracrine immune mediator changes.","evidence":"Genome-edited models with ATAC-seq/ChIP-seq, single-cell RNA-seq, and clinical samples","pmids":["35440136"],"confidence":"High","gaps":["Causal contribution of PR insulated neighborhood to phenotype not isolated","Immune crosstalk consequences for therapy untested"]},{"year":2023,"claim":"Defined a non-transcription-factor neural role, showing Esr1+ lateral hypothalamic neurons projecting to the lateral habenula encode aversion and a persistent aversive state.","evidence":"Patch-seq classification, optogenetic activation, large-scale recordings, and behavioral assays","pmids":["37349481"],"confidence":"High","gaps":["Whether ERα transcriptional activity is required for this circuit function not established","Ligand dependence of the neural phenotype unknown"]},{"year":2024,"claim":"Resolved a structural determinant of drug binding, identifying ERα F404 as a pi-stacking residue whose mutation selectively abolishes fulvestrant efficacy while sparing oral degraders.","evidence":"In silico structural modeling, in vitro single/compound mutant models, and clinical ctDNA sequencing from PlasmaMATCH","pmids":["37982575"],"confidence":"Medium","gaps":["Crystallographic confirmation of the pi-stacking bond not provided","Clinical frequency and prognostic impact of F404 mutations not established"]},{"year":null,"claim":"How ERα PTM codes, cofactor tethering, and mutation-driven cistrome reprogramming are integrated into a unified, predictively targetable mechanism remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model unifying neomorphic chromatin recruitment with LBD mutation","E3 ligases governing ERα ubiquitination states incompletely mapped","Link between transcriptional ERα biology and Esr1+ neuronal function unexplored"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,5,7,11]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[2,11]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,1,11]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,7,11]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[5,7,12,16]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[6,7,13]}],"complexes":[],"partners":["ESR2","SP1","FOXA1","IGF-1R","ZEB1","ZNF143"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P03372","full_name":"Estrogen receptor","aliases":["ER-alpha","Estradiol receptor","Nuclear receptor subfamily 3 group A member 1"],"length_aa":595,"mass_kda":66.2,"function":"Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Essential for MTA1-mediated transcriptional regulation of BRCA1 and BCAS3 (PubMed:17922032). Maintains neuronal survival in response to ischemic reperfusion injury when in the presence of circulating estradiol (17-beta-estradiol/E2) (By similarity) Involved in activation of NOS3 and endothelial nitric oxide production (PubMed:21937726). Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full-length receptor (PubMed:10970861). Binds to ERE and inhibits isoform 1 (PubMed:10970861)","subcellular_location":"Nucleus; Golgi apparatus; Cell membrane","url":"https://www.uniprot.org/uniprotkb/P03372/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ESR1","classification":"Not Classified","n_dependent_lines":17,"n_total_lines":1208,"dependency_fraction":0.014072847682119206},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ESR1","total_profiled":1310},"omim":[{"mim_id":"621023","title":"RNA-BINDING MOTIF PROTEIN 23; RBM23","url":"https://www.omim.org/entry/621023"},{"mim_id":"620552","title":"CUE DOMAIN-CONTAINING PROTEIN 1; CUEDC1","url":"https://www.omim.org/entry/620552"},{"mim_id":"619624","title":"LEMUR TYROSINE KINASE 3; LMTK3","url":"https://www.omim.org/entry/619624"},{"mim_id":"619448","title":"STEROID RECEPTOR-ASSOCIATED AND -REGULATED PROTEIN; SRARP","url":"https://www.omim.org/entry/619448"},{"mim_id":"619403","title":"COLON CANCER-ASSOCIATED TRANSCRIPT 2, NONCODING; CCAT2","url":"https://www.omim.org/entry/619403"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"cervix","ntpm":80.7},{"tissue":"endometrium 1","ntpm":103.7},{"tissue":"fallopian tube","ntpm":61.1}],"url":"https://www.proteinatlas.org/search/ESR1"},"hgnc":{"alias_symbol":["ER","NR3A1","Era","ER-alpha"],"prev_symbol":["ESR"]},"alphafold":{"accession":"P03372","domains":[{"cath_id":"3.30.50.10","chopping":"193-247","consensus_level":"high","plddt":93.3795,"start":193,"end":247},{"cath_id":"1.10.565.10","chopping":"306-549","consensus_level":"high","plddt":91.522,"start":306,"end":549}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P03372","model_url":"https://alphafold.ebi.ac.uk/files/AF-P03372-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P03372-F1-predicted_aligned_error_v6.png","plddt_mean":66.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ESR1","jax_strain_url":"https://www.jax.org/strain/search?query=ESR1"},"sequence":{"accession":"P03372","fasta_url":"https://rest.uniprot.org/uniprotkb/P03372.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P03372/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P03372"}},"corpus_meta":[{"pmid":"14993442","id":"PMC_14993442","title":"Estrogen signaling: a subtle balance between ER alpha and ER beta.","date":"2003","source":"Molecular interventions","url":"https://pubmed.ncbi.nlm.nih.gov/14993442","citation_count":572,"is_preprint":false},{"pmid":"26122181","id":"PMC_26122181","title":"ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.","date":"2015","source":"Nature reviews. Clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26122181","citation_count":544,"is_preprint":false},{"pmid":"11375934","id":"PMC_11375934","title":"A novel ER alpha-mannosidase-like protein accelerates ER-associated degradation.","date":"2001","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/11375934","citation_count":365,"is_preprint":false},{"pmid":"27986707","id":"PMC_27986707","title":"Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.","date":"2016","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/27986707","citation_count":323,"is_preprint":false},{"pmid":"18446233","id":"PMC_18446233","title":"Pancreatic insulin content regulation by the estrogen receptor ER alpha.","date":"2008","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18446233","citation_count":315,"is_preprint":false},{"pmid":"17417639","id":"PMC_17417639","title":"Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.","date":"2007","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17417639","citation_count":284,"is_preprint":false},{"pmid":"29438694","id":"PMC_29438694","title":"Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations.","date":"2018","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/29438694","citation_count":221,"is_preprint":false},{"pmid":"31318440","id":"PMC_31318440","title":"ESR1 mutations in breast cancer.","date":"2019","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31318440","citation_count":209,"is_preprint":false},{"pmid":"16024756","id":"PMC_16024756","title":"Estrogen and the brain: beyond ER-alpha, ER-beta, and 17beta-estradiol.","date":"2005","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/16024756","citation_count":129,"is_preprint":false},{"pmid":"34621045","id":"PMC_34621045","title":"ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.","date":"2021","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34621045","citation_count":121,"is_preprint":false},{"pmid":"14762170","id":"PMC_14762170","title":"Estrogen receptors ER alpha and ER beta in proliferation in the rodent mammary gland.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/14762170","citation_count":114,"is_preprint":false},{"pmid":"17118173","id":"PMC_17118173","title":"Estrogen receptor-alpha (ER-alpha) and defects in uterine receptivity in women.","date":"2006","source":"Reproductive biology and endocrinology : RB&E","url":"https://pubmed.ncbi.nlm.nih.gov/17118173","citation_count":113,"is_preprint":false},{"pmid":"20616674","id":"PMC_20616674","title":"A review of estrogen receptor alpha gene (ESR1) polymorphisms, mood, and cognition.","date":"2010","source":"Menopause (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/20616674","citation_count":109,"is_preprint":false},{"pmid":"40454637","id":"PMC_40454637","title":"First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer.","date":"2025","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40454637","citation_count":91,"is_preprint":false},{"pmid":"31106278","id":"PMC_31106278","title":"ESR1 alterations and metastasis in estrogen receptor positive breast cancer.","date":"2019","source":"Journal of cancer metastasis and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/31106278","citation_count":90,"is_preprint":false},{"pmid":"19328202","id":"PMC_19328202","title":"Estrogen receptor-alpha (ER-alpha) suppresses expression of its variant ER-alpha 36.","date":"2009","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/19328202","citation_count":74,"is_preprint":false},{"pmid":"15582272","id":"PMC_15582272","title":"Estrogen and the brain: beyond ER-alpha and ER-beta.","date":"2004","source":"Experimental gerontology","url":"https://pubmed.ncbi.nlm.nih.gov/15582272","citation_count":72,"is_preprint":false},{"pmid":"28383555","id":"PMC_28383555","title":"ZEB1 induces ER-α promoter hypermethylation and confers antiestrogen resistance in breast cancer.","date":"2017","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/28383555","citation_count":72,"is_preprint":false},{"pmid":"37009655","id":"PMC_37009655","title":"CircPVT1 promotes ER-positive breast tumorigenesis and drug resistance by targeting ESR1 and MAVS.","date":"2023","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/37009655","citation_count":71,"is_preprint":false},{"pmid":"29196658","id":"PMC_29196658","title":"Estrogen receptor 1 (ESR1) regulates VEGFA in adipose tissue.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29196658","citation_count":71,"is_preprint":false},{"pmid":"15507513","id":"PMC_15507513","title":"Differential regulation of estrogen receptor (ER)alpha and ERbeta in primate mammary gland.","date":"2004","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15507513","citation_count":69,"is_preprint":false},{"pmid":"24487689","id":"PMC_24487689","title":"Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight.","date":"2014","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/24487689","citation_count":67,"is_preprint":false},{"pmid":"28679775","id":"PMC_28679775","title":"Detection of Activating Estrogen Receptor Gene (ESR1) Mutations in Single Circulating Tumor Cells.","date":"2017","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/28679775","citation_count":62,"is_preprint":false},{"pmid":"35078818","id":"PMC_35078818","title":"Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis.","date":"2022","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/35078818","citation_count":61,"is_preprint":false},{"pmid":"35440136","id":"PMC_35440136","title":"ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35440136","citation_count":60,"is_preprint":false},{"pmid":"30511377","id":"PMC_30511377","title":"miR-4324-RACGAP1-STAT3-ESR1 feedback loop inhibits proliferation and metastasis of bladder cancer.","date":"2019","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30511377","citation_count":59,"is_preprint":false},{"pmid":"17510501","id":"PMC_17510501","title":"Association between estrogen receptor alpha (ESR1) gene polymorphisms and severe preeclampsia.","date":"2007","source":"Hypertension research : official journal of the Japanese Society of Hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/17510501","citation_count":58,"is_preprint":false},{"pmid":"12021204","id":"PMC_12021204","title":"Expression of ER-alpha and ER-beta in the hamster ovary: differential regulation by gonadotropins and ovarian steroid hormones.","date":"2002","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/12021204","citation_count":56,"is_preprint":false},{"pmid":"19861523","id":"PMC_19861523","title":"DNA hypermethylation of ESR1 and PGR in breast cancer: pathologic and epidemiologic associations.","date":"2009","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19861523","citation_count":54,"is_preprint":false},{"pmid":"12351687","id":"PMC_12351687","title":"Colocalization and ligand-dependent discrete distribution of the estrogen receptor (ER)alpha and ERbeta.","date":"2002","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/12351687","citation_count":53,"is_preprint":false},{"pmid":"36336145","id":"PMC_36336145","title":"ESR1 activating mutations: From structure to clinical application.","date":"2022","source":"Biochimica et biophysica acta. Reviews on cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36336145","citation_count":49,"is_preprint":false},{"pmid":"31188645","id":"PMC_31188645","title":"ESR1 mutations: a new biomarker in breast cancer.","date":"2019","source":"Expert review of molecular diagnostics","url":"https://pubmed.ncbi.nlm.nih.gov/31188645","citation_count":48,"is_preprint":false},{"pmid":"19760036","id":"PMC_19760036","title":"Potentially functional polymorphisms in ESR1 and breast cancer risk: a meta-analysis.","date":"2009","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/19760036","citation_count":48,"is_preprint":false},{"pmid":"23684889","id":"PMC_23684889","title":"Chromatin and epigenetic determinants of estrogen receptor alpha (ESR1) signaling.","date":"2013","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/23684889","citation_count":45,"is_preprint":false},{"pmid":"24735329","id":"PMC_24735329","title":"ESR1 and ESR2 differentially regulate daily and circadian activity rhythms in female mice.","date":"2014","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/24735329","citation_count":44,"is_preprint":false},{"pmid":"12973717","id":"PMC_12973717","title":"Expression of estrogen receptor alpha (ER alpha) in the rat temporomandibular joint.","date":"2003","source":"The anatomical record. Part A, Discoveries in molecular, cellular, and evolutionary biology","url":"https://pubmed.ncbi.nlm.nih.gov/12973717","citation_count":44,"is_preprint":false},{"pmid":"29736566","id":"PMC_29736566","title":"The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer.","date":"2018","source":"Hormones & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29736566","citation_count":43,"is_preprint":false},{"pmid":"32592004","id":"PMC_32592004","title":"Intrinsic and Extrinsic Factors Governing the Transcriptional Regulation of ESR1.","date":"2020","source":"Hormones & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32592004","citation_count":40,"is_preprint":false},{"pmid":"31100494","id":"PMC_31100494","title":"Estradiol stimulates adipogenesis and Slc2a4/GLUT4 expression via ESR1-mediated activation of CEBPA.","date":"2019","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/31100494","citation_count":39,"is_preprint":false},{"pmid":"24586459","id":"PMC_24586459","title":"Xenoestrogens alter estrogen receptor (ER) α intracellular levels.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24586459","citation_count":37,"is_preprint":false},{"pmid":"15944240","id":"PMC_15944240","title":"Expression of estrogen receptor ESR1 and its 46-kDa variant in the gubernaculum testis.","date":"2005","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/15944240","citation_count":36,"is_preprint":false},{"pmid":"15709176","id":"PMC_15709176","title":"Polymorphisms in ER-alpha gene interact with estrogen receptor status in breast cancer survival.","date":"2005","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/15709176","citation_count":36,"is_preprint":false},{"pmid":"36686845","id":"PMC_36686845","title":"ESR1 fusions and therapeutic resistance in metastatic breast cancer.","date":"2023","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36686845","citation_count":35,"is_preprint":false},{"pmid":"33323970","id":"PMC_33323970","title":"Hormonal modulation of ESR1 mutant metastasis.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33323970","citation_count":35,"is_preprint":false},{"pmid":"23733894","id":"PMC_23733894","title":"Estrogen receptor α (ESR1) over-expression mediated apoptosis in Hep3B cells by binding with SP1 proteins.","date":"2013","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/23733894","citation_count":35,"is_preprint":false},{"pmid":"20172536","id":"PMC_20172536","title":"Estrogen receptor alpha (ESR-1) associations with psychological traits in women with PMDD and controls.","date":"2010","source":"Journal of psychiatric research","url":"https://pubmed.ncbi.nlm.nih.gov/20172536","citation_count":35,"is_preprint":false},{"pmid":"25526766","id":"PMC_25526766","title":"ESR1 and ESR2 gene polymorphisms are associated with human reproduction outcomes in Brazilian women.","date":"2014","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/25526766","citation_count":34,"is_preprint":false},{"pmid":"20375995","id":"PMC_20375995","title":"Estrogen receptor 1 gene (ESR1) is associated with restrictive anorexia nervosa.","date":"2010","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20375995","citation_count":34,"is_preprint":false},{"pmid":"21356307","id":"PMC_21356307","title":"17β-Estradiol-induced cell proliferation requires estrogen receptor (ER) α monoubiquitination.","date":"2011","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/21356307","citation_count":34,"is_preprint":false},{"pmid":"18720455","id":"PMC_18720455","title":"Oestrogen receptor gene (ESR1) amplification is frequent in endometrial carcinoma and its precursor lesions.","date":"2008","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/18720455","citation_count":33,"is_preprint":false},{"pmid":"29881378","id":"PMC_29881378","title":"Estrogen Receptor-Alpha (ESR1) Governs the Lower Female Reproductive Tract Vulnerability to Candida albicans.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29881378","citation_count":33,"is_preprint":false},{"pmid":"19812388","id":"PMC_19812388","title":"Selective disruption of ER{alpha} DNA-binding activity alters uterine responsiveness to estradiol.","date":"2009","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/19812388","citation_count":33,"is_preprint":false},{"pmid":"37982575","id":"PMC_37982575","title":"ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer.","date":"2024","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/37982575","citation_count":32,"is_preprint":false},{"pmid":"37349481","id":"PMC_37349481","title":"Esr1+ hypothalamic-habenula neurons shape aversive states.","date":"2023","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/37349481","citation_count":32,"is_preprint":false},{"pmid":"30728052","id":"PMC_30728052","title":"Aberrant DNA methylation suppresses expression of estrogen receptor 1 (ESR1) in ovarian endometrioma.","date":"2019","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/30728052","citation_count":31,"is_preprint":false},{"pmid":"34709177","id":"PMC_34709177","title":"Disrupted PGR-B and ESR1 signaling underlies defective decidualization linked to severe preeclampsia.","date":"2021","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/34709177","citation_count":31,"is_preprint":false},{"pmid":"35538119","id":"PMC_35538119","title":"Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer.","date":"2022","source":"NPJ breast cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35538119","citation_count":30,"is_preprint":false},{"pmid":"22061094","id":"PMC_22061094","title":"ESR1 in myocardial infarction.","date":"2011","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22061094","citation_count":29,"is_preprint":false},{"pmid":"12718718","id":"PMC_12718718","title":"ER-alpha variants and the cardiovascular effects of hormone replacement therapy.","date":"2003","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/12718718","citation_count":29,"is_preprint":false},{"pmid":"28799536","id":"PMC_28799536","title":"Estrogen receptor (ESR1) mutation in bone metastases from breast cancer.","date":"2017","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/28799536","citation_count":29,"is_preprint":false},{"pmid":"30275758","id":"PMC_30275758","title":"Estrogen Receptor 1 (ESR1) Enhances Slc2a4/GLUT4 Expression by a SP1 Cooperative Mechanism.","date":"2018","source":"International journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30275758","citation_count":29,"is_preprint":false},{"pmid":"17446729","id":"PMC_17446729","title":"Estrogen Receptor 1 gene (ESR1) variants in Alzheimer's disease. Results of a meta-analysis.","date":"2007","source":"Aging clinical and experimental research","url":"https://pubmed.ncbi.nlm.nih.gov/17446729","citation_count":29,"is_preprint":false},{"pmid":"30820448","id":"PMC_30820448","title":"ESR1 mutations in metastatic lobular breast cancer patients.","date":"2019","source":"NPJ breast cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30820448","citation_count":29,"is_preprint":false},{"pmid":"29666928","id":"PMC_29666928","title":"Implications of ESR1 Mutations in Hormone Receptor-Positive Breast Cancer.","date":"2018","source":"Current treatment options in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29666928","citation_count":28,"is_preprint":false},{"pmid":"37922653","id":"PMC_37922653","title":"Formononetin ameliorates airway inflammation by suppressing ESR1/NLRP3/Caspase-1 signaling in asthma.","date":"2023","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/37922653","citation_count":28,"is_preprint":false},{"pmid":"35843886","id":"PMC_35843886","title":"The E3 Ligase TRIM4 Facilitates SET Ubiquitin-Mediated Degradation to Enhance ER-α Action in Breast Cancer.","date":"2022","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/35843886","citation_count":27,"is_preprint":false},{"pmid":"30355675","id":"PMC_30355675","title":"Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer.","date":"2018","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/30355675","citation_count":27,"is_preprint":false},{"pmid":"33639680","id":"PMC_33639680","title":"Daidzein Induces Intrinsic Pathway of Apoptosis along with ER α/β Ratio Alteration and ROS Production.","date":"2021","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/33639680","citation_count":25,"is_preprint":false},{"pmid":"33937624","id":"PMC_33937624","title":"Preexisting Somatic Mutations of Estrogen Receptor Alpha (ESR1) in Early-Stage Primary Breast Cancer.","date":"2021","source":"JNCI cancer spectrum","url":"https://pubmed.ncbi.nlm.nih.gov/33937624","citation_count":24,"is_preprint":false},{"pmid":"33257837","id":"PMC_33257837","title":"RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer.","date":"2020","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33257837","citation_count":24,"is_preprint":false},{"pmid":"20505342","id":"PMC_20505342","title":"DNA methylation of ESR-1 and N-33 in colorectal mucosa of patients with ulcerative colitis (UC).","date":"2010","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/20505342","citation_count":23,"is_preprint":false},{"pmid":"25778331","id":"PMC_25778331","title":"Association between estrogen receptor 1 (ESR1) genetic variations and cancer risk: a meta-analysis.","date":"2015","source":"Journal of B.U.ON. : official journal of the Balkan Union of Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25778331","citation_count":22,"is_preprint":false},{"pmid":"24647635","id":"PMC_24647635","title":"Association of polymorphisms in estrogen receptors (ESR1 and ESR2) with male infertility: a meta-analysis and systematic review.","date":"2014","source":"Journal of assisted reproduction and genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24647635","citation_count":22,"is_preprint":false},{"pmid":"28043824","id":"PMC_28043824","title":"ESR1 and its antagonist fulvestrant in pituitary adenomas.","date":"2016","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/28043824","citation_count":21,"is_preprint":false},{"pmid":"16242874","id":"PMC_16242874","title":"ESR1 and APOE gene polymorphisms, serum lipids, and hormonal replacement therapy.","date":"2005","source":"Maturitas","url":"https://pubmed.ncbi.nlm.nih.gov/16242874","citation_count":21,"is_preprint":false},{"pmid":"29664547","id":"PMC_29664547","title":"HSD3B2, HSD17B1, HSD17B2, ESR1, ESR2 and AR expression in infertile women with endometriosis.","date":"2018","source":"Ginekologia polska","url":"https://pubmed.ncbi.nlm.nih.gov/29664547","citation_count":21,"is_preprint":false},{"pmid":"32169631","id":"PMC_32169631","title":"Association of estrogen receptor gene variants (ESR1 and ESR2) with polycystic ovary syndrome in Tunisia.","date":"2020","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/32169631","citation_count":21,"is_preprint":false},{"pmid":"24859835","id":"PMC_24859835","title":"The influence of ESR1 rs9340799 and ESR2 rs1256049 polymorphisms on prostate cancer risk.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24859835","citation_count":21,"is_preprint":false},{"pmid":"26334887","id":"PMC_26334887","title":"Impact of ESR1 Gene Polymorphisms on Migraine Susceptibility: A Meta-Analysis.","date":"2015","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26334887","citation_count":21,"is_preprint":false},{"pmid":"23131391","id":"PMC_23131391","title":"RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy.","date":"2012","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23131391","citation_count":20,"is_preprint":false},{"pmid":"34961764","id":"PMC_34961764","title":"ESR1 hotspot mutations in endometrial stromal sarcoma with high-grade transformation and endocrine treatment.","date":"2021","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/34961764","citation_count":19,"is_preprint":false},{"pmid":"23203086","id":"PMC_23203086","title":"An advanced Electron Spin Resonance (ESR) spin-trapping and LC/(ESR)/MS technique for the study of lipid peroxidation.","date":"2012","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/23203086","citation_count":19,"is_preprint":false},{"pmid":"30976784","id":"PMC_30976784","title":"Characterizing the selectivity of ER α-glucosidase inhibitors.","date":"2019","source":"Glycobiology","url":"https://pubmed.ncbi.nlm.nih.gov/30976784","citation_count":17,"is_preprint":false},{"pmid":"32544536","id":"PMC_32544536","title":"Estrogen receptor (ESR1 and ESR2)-mediated activation of eNOS-NO-cGMP pathway facilitates high altitude acclimatization.","date":"2020","source":"Nitric oxide : biology and chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32544536","citation_count":17,"is_preprint":false},{"pmid":"34101078","id":"PMC_34101078","title":"Evaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA.","date":"2021","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/34101078","citation_count":17,"is_preprint":false},{"pmid":"23285017","id":"PMC_23285017","title":"δEF1 down-regulates ER-α expression and confers tamoxifen resistance in breast cancer.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23285017","citation_count":17,"is_preprint":false},{"pmid":"28717394","id":"PMC_28717394","title":"Immunohistochemical expression of ER-α and PR in papillary thyroid carcinoma.","date":"2017","source":"Ecancermedicalscience","url":"https://pubmed.ncbi.nlm.nih.gov/28717394","citation_count":16,"is_preprint":false},{"pmid":"32150902","id":"PMC_32150902","title":"Interaction of Coumarin Phytoestrogens with ERα and ERβ: A Molecular Dynamics Simulation Study.","date":"2020","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/32150902","citation_count":16,"is_preprint":false},{"pmid":"33540646","id":"PMC_33540646","title":"ESR1 ChIP-Seq Identifies Distinct Ligand-Free ESR1 Genomic Binding Sites in Human Hepatocytes and Liver Tissue.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33540646","citation_count":16,"is_preprint":false},{"pmid":"24568551","id":"PMC_24568551","title":"The ESR1 gene in unexplained recurrent spontaneous abortion.","date":"2014","source":"Systems biology in reproductive medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24568551","citation_count":16,"is_preprint":false},{"pmid":"34710471","id":"PMC_34710471","title":"Transcriptional regulation of CYP19A1 expression in chickens: ESR1, ESR2 and NR5A2 form a functional network.","date":"2021","source":"General and comparative endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/34710471","citation_count":15,"is_preprint":false},{"pmid":"22644675","id":"PMC_22644675","title":"MTA1 expression correlates significantly with ER-alpha methylation in breast cancer.","date":"2012","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22644675","citation_count":15,"is_preprint":false},{"pmid":"25428437","id":"PMC_25428437","title":"Association between estrogen receptora gene (ESR1) PvuII (T/C) and XbaI (A/G) polymorphisms and premature ovarian failure risk: evidence from a meta-analysis.","date":"2014","source":"Journal of assisted reproduction and genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25428437","citation_count":15,"is_preprint":false},{"pmid":"31786857","id":"PMC_31786857","title":"Association of rs2234693 and rs9340799 polymorphisms of ESR1 gene in breast cancer of Mexican population.","date":"2019","source":"Journal of B.U.ON. : official journal of the Balkan Union of Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31786857","citation_count":15,"is_preprint":false},{"pmid":"26808832","id":"PMC_26808832","title":"Estrogen Receptor Alpha (ESR1)-Dependent Regulation of the Mouse Oviductal Transcriptome.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26808832","citation_count":14,"is_preprint":false},{"pmid":"32572901","id":"PMC_32572901","title":"The crosstalk between IGF-1R and ER-α in the proliferation and anti-inflammation of nucleus pulposus cells.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32572901","citation_count":14,"is_preprint":false},{"pmid":"35430461","id":"PMC_35430461","title":"IL-27 promotes decidualization via the STAT3-ESR/PGR regulatory axis.","date":"2022","source":"Journal of reproductive immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35430461","citation_count":14,"is_preprint":false},{"pmid":"34545128","id":"PMC_34545128","title":"The rs9340799 polymorphism of the estrogen receptor alpha (ESR1) gene and its association with breast cancer susceptibility.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34545128","citation_count":14,"is_preprint":false},{"pmid":"29234250","id":"PMC_29234250","title":"Are We Ready to Use ESR1 Mutations in Clinical Practice?","date":"2017","source":"Breast care (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/29234250","citation_count":14,"is_preprint":false},{"pmid":"24023309","id":"PMC_24023309","title":"ESR1 gene amplification in endometrial carcinomas: a clinicopathological analysis.","date":"2013","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24023309","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51238,"output_tokens":5498,"usd":0.118092,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14332,"output_tokens":4034,"usd":0.086255,"stage2_stop_reason":"end_turn"},"total_usd":0.204347,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"ERα and ERβ form functional heterodimers when coexpressed, and ERβ exhibits an inhibitory action on ERα-mediated gene expression; both receptors colocalize in the same discrete nuclear clusters upon ligand activation, with cluster formation requiring at least the latter part of AF-1, the DNA-binding domain, nuclear matrix binding domain, and AF-2/ligand-binding domain of ERα.\",\n      \"method\": \"Live-cell imaging with GFP-tagged fusion proteins, deletion mutant analysis, colocalization with hyperacetylated histone H4 and Brg-1 (chromatin remodeling complex component)\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — live-cell imaging with deletion mutants and functional colocalization markers in single study, single lab\",\n      \"pmids\": [\"12351687\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ERα receives the estrogen proliferation signal in mammary epithelial cells and initiates DNA synthesis, then is lost from the nucleus; ERβ facilitates the return of ERα to the nucleus and restores responsiveness to estradiol. Both ERα and ERβ can independently mediate estradiol-induced proliferation.\",\n      \"method\": \"BrdUrd incorporation assay in WT and ERβ-knockout mice treated with E2, tamoxifen, or ERβ-specific agonist; immunofluorescence with specific antibodies for ERα and ERβ localization\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic KO model with orthogonal methods (BrdU, immunofluorescence, multiple ligand conditions), replicated across genotypes\",\n      \"pmids\": [\"14762170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ERα directly binds to the estrogen-responsive element (ERE) DNA motif to regulate a distinct set of uterine genes; loss of ERα DNA-binding activity (KIKO knock-in mouse) reveals that 38% of wild-type E2-regulated transcripts are also regulated via non-ERE tethered mechanisms, and an entirely unique set of 1438 transcripts is regulated only in the KIKO context. Canonical pathways including Jak/Stat are regulated similarly by ERE and non-ERE pathways, while Wnt/β-catenin pathway members differ.\",\n      \"method\": \"In vivo knock-in mouse model (KIKO) lacking ERα DNA-binding function; microarray gene expression profiling; comparison of WT, KIKO, and αERKO genotypes\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic knock-in with loss-of-function and genome-wide expression profiling across three genotypes\",\n      \"pmids\": [\"19812388\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ERα monoubiquitination is required for E2-induced ERα phosphorylation at Ser118, transcriptional activity, extranuclear AKT activation, cyclin D1 promoter activation, and cell proliferation; mutation of ERα monoubiquitination sites also disrupts E2-induced ERα association with IGF-1R.\",\n      \"method\": \"Site-directed mutagenesis of ERα monoubiquitination sites; cell proliferation assays; western blotting for phospho-Ser118, AKT activation; cyclin D1 promoter reporter assays; co-immunoprecipitation for IGF-1R interaction\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — mutagenesis combined with multiple functional readouts (signaling, transcription, proliferation) in single lab\",\n      \"pmids\": [\"21356307\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ERα (ESR1) overexpression in ER-negative Hep3B cells induces apoptosis via a ligand-dependent interaction with SP1 protein; the ERα-SP1 complex binds proximal and distal SP1 sites in the TNFα gene promoter, activating TNFα expression and downstream caspase-3 activation. Deletion of SP1 binding sites in the TNFα promoter abolished ERα-mediated promoter activity.\",\n      \"method\": \"DNA fragmentation assay; flow cytometry; western blotting for active caspase-3 and TNFα; co-immunoprecipitation of ERα and SP1; TNFα promoter reporter assays with SP1-site deletions; mithramycin (SP1 inhibitor) treatment\",\n      \"journal\": \"Journal of molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus promoter deletion experiments and pharmacological validation, single lab\",\n      \"pmids\": [\"23733894\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ESR1 somatic mutations clustered in the ligand-binding domain (LBD) confer ligand-independent ER transcriptional activity in metastatic breast cancer; these gain-of-function mutations (e.g., Y537S, D538G) promote estrogen-independent tumor growth and confer partial to full resistance to endocrine therapies including aromatase inhibitors and fulvestrant.\",\n      \"method\": \"Characterization of ESR1 mutations from >900 patients; in vitro functional assays for constitutive activity; in vivo xenograft models; comparison of sensitivity to ER antagonists including fulvestrant and AZD9496\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — large clinical dataset combined with in vitro functional assays and in vivo xenograft models, replicated across multiple mutation variants\",\n      \"pmids\": [\"27986707\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ZEB1 represses ESR1 transcription by forming a ZEB1/DNMT3B/HDAC1 complex on the ESR1 promoter, leading to DNA hypermethylation and silencing of ERα; siRNA depletion of ZEB1 causes ESR1 promoter demethylation and restores ERα expression and antiestrogen sensitivity.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP); co-immunoprecipitation of ZEB1/DNMT3B/HDAC1 complex; siRNA knockdown; bisulfite sequencing; reporter assays; nude mouse xenograft model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (ChIP, Co-IP, siRNA, bisulfite sequencing, in vivo xenograft) in single study\",\n      \"pmids\": [\"28383555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ESR1 LBD mutations exhibit both ligand-independent functions that mimic estradiol-bound wild-type ER and allele-specific neomorphic (neomorphic/gain-of-function) chromatin recruitment properties that promote a pro-metastatic transcriptional program; genome-wide ER binding site analysis identified mutant ER-unique recruitment sites mediating allele-specific transcriptional programs.\",\n      \"method\": \"ChIP-seq for genome-wide ER binding; genetic screens for essential genes; transcriptional network analysis in breast cancer models with clinically relevant ER mutations\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide ChIP-seq combined with genetic screens, multiple cell models, rigorous controls\",\n      \"pmids\": [\"29438694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ESR1 activation in adipocytes increases nuclear SP1 protein content, the SP1/ESR1 complex formation, and SP1 binding to the Slc2a4 gene promoter, resulting in increased Slc2a4/GLUT4 expression; this ESR1/SP1 cooperative mechanism is specific to ESR1 (not ESR2) and is demonstrated via immunoprecipitation of SP1/ESR1 complex and EMSA.\",\n      \"method\": \"Western blotting; immunoprecipitation of SP1/ESR1 complex; EMSA (electrophoretic mobility shift assay) for SP1 binding to Slc2a4 promoter; ESR1 agonist (PPT) and antagonist; siRNA knockdown\",\n      \"journal\": \"International journal of medical sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP and EMSA with orthogonal agonist/antagonist and siRNA controls, single lab\",\n      \"pmids\": [\"30275758\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Estradiol stimulates adipogenesis and Slc2a4/GLUT4 expression via an ESR1-dependent, CEBPA-mediated pathway; ESR1 silencing abrogates E2-induced nuclear CEBPA content, Slc2a4/GLUT4 expression, and GLUT4 translocation to the cell membrane.\",\n      \"method\": \"siRNA-mediated Esr1 silencing in 3T3-L1 adipocytes; western blotting; RT-qPCR; GLUT4 translocation assay\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA loss-of-function with multiple molecular readouts (protein content, mRNA, translocation), single lab\",\n      \"pmids\": [\"31100494\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"RON kinase is hyperactivated in ESR1 Y537S mutant breast cancer cells and interacts with IGF-1R; RON/PI3K hyperactivity is regulated by mutant ER (reduced by endocrine therapies) and RON inhibition combined with endocrine therapy decreases organoid growth and reduces metastasis in an ESR1 Y537S PDX model.\",\n      \"method\": \"Proteomic kinome analysis; phospho-immunoblot; pharmacological and genetic inhibition of RON and IGF-1R; organoid growth assays; in vivo PDX metastatic model\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — kinome-wide screen plus genetic/pharmacological validation and in vivo PDX model, single lab\",\n      \"pmids\": [\"33257837\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ESR1 ChIP-seq in human hepatocytes and liver tissue identifies both ligand-dependent and ligand-independent (unliganded) ESR1 genomic binding sites with distinct genomic localization, pathway enrichment, and cofactor co-localization patterns; ligand-free ESR1 shows co-enrichment with ZNF143 and regulates CYP genes involved in drug metabolism.\",\n      \"method\": \"ChIP-seq in human liver samples and hepatocytes with/without 17β-estradiol; pathway enrichment analysis; cofactor co-localization analysis\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide ChIP-seq in primary human tissue, single study, no mutagenesis validation\",\n      \"pmids\": [\"33540646\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ESR1 hotspot mutations (Y537S, D538G) reprogram the ER cistrome via de novo FOXA1-driven chromatin remodeling and secondary transcriptional regulation; these mutations alter desmosome/gap junction genes and the TIMP3/MMP axis, functionally enhancing cell-cell contacts while decreasing cell-extracellular matrix adhesion, thereby promoting metastatic CTC cluster formation.\",\n      \"method\": \"Genome-edited ESR1 mutant cell models; transcriptomic and cistrome profiling; in vivo CTC cluster analysis; five independent breast cancer cohorts; Wnt/ER co-targeting experiments\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-edited models with cistrome/transcriptome profiling, multiple in vivo and in vitro readouts, and five clinical cohorts\",\n      \"pmids\": [\"35078818\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ESR1 mutant cells show induction of basal cytokeratins (BCKs) independent of ER binding, associated with chromatin reprogramming centered on a progesterone receptor-orchestrated insulated neighborhood; ESR1 mutant tumors also show elevated S100A8/S100A9 immune mediators via tumor-stroma paracrine crosstalk.\",\n      \"method\": \"Genome-edited ESR1 mutant cell models; ATAC-seq/ChIP-seq for chromatin reprogramming; single-cell RNA-seq from metastatic tumors; analysis of clinical samples\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-edited models combined with chromatin profiling (ATAC-seq/ChIP-seq), single-cell RNA-seq, and clinical validation\",\n      \"pmids\": [\"35440136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TRIM4 E3 ligase catalyzes K48-linked polyubiquitination of SET at K150 and K172, promoting SET proteasomal degradation; loss of SET releases p53 and PP2A, which in turn promote ESR1 gene transcription and mRNA stability, thereby enhancing ERα expression and tamoxifen sensitivity.\",\n      \"method\": \"In vitro and in vivo ubiquitination assays; co-immunoprecipitation of TRIM4-SET (mapping to RING/B-box and SET C-terminus); domain mapping; western blotting; siRNA/overexpression experiments\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP domain mapping plus ubiquitination assay with multiple functional readouts, single lab\",\n      \"pmids\": [\"35843886\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Esr1-expressing (Esr1+) neurons in the lateral hypothalamic area (LHA) projecting to the lateral habenula (LHb) induce aversion and a behaviorally persistent aversive state upon repeated optogenetic activation; these neurons show sex-specific shifts in intrinsic bursting properties following unpredictable mild shocks in female mice, associated with stress sensitivity.\",\n      \"method\": \"Patch-seq multimodal classification; optogenetic stimulation; large-scale neural recordings; behavioral assays; electrophysiology\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Patch-seq guided classification with optogenetic functional validation, large-scale recordings, and behavioral assays in defined Esr1+ cell population\",\n      \"pmids\": [\"37349481\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ESR1 F404 residue contributes to fulvestrant binding to ERα through a pi-stacking bond; acquired F404L/I/V mutations (in cis with activating mutations) disrupt this bond, causing overt resistance to fulvestrant but not to oral ERα degraders; compound mutations D538G+F404L and E380Q+F404L confer fulvestrant resistance in vitro.\",\n      \"method\": \"In silico structural modeling of F404-fulvestrant pi-stacking; in vitro cell line models with single and compound ESR1 mutations; sequencing of baseline and end-of-treatment ctDNA from clinical trial (PlasmaMATCH); pharmacological testing with oral ERα degraders\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — structural modeling with in vitro functional validation and clinical ctDNA sequencing, single study\",\n      \"pmids\": [\"37982575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ERα suppresses expression of its variant ERα36 in an estrogen-independent manner by acting on the ERα36 promoter; ERα36 itself can release this suppression.\",\n      \"method\": \"Promoter cloning; transient co-transfection reporter assays; transcription initiation site mapping\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — reporter assay only, single lab, no endogenous ChIP confirmation\",\n      \"pmids\": [\"19328202\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ERα activation (via estradiol or ESR1 agonist PPT) increases pancreatic beta-cell insulin content, insulin gene expression, and insulin release through ERK1/2 signaling; this effect is absent in ERα-knockout mice and is mimicked by bisphenol-A.\",\n      \"method\": \"ERα and ERβ agonists; ERαKO and ERβKO mouse models; ERK1/2 pathway inhibition; gene expression analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO models combined with pharmacological agonist/antagonist approach and kinase pathway analysis, single lab\",\n      \"pmids\": [\"18446233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ESR1 (ERα) activation by E2 induces binding of HIF1A to the VEGFA gene promoter in adipocytes, promoting VEGFA expression; ESR1-selective agonist (PPT) mimics this effect, while ESR1 siRNA knockdown decreases VEGFA and prevents E2-mediated modulation; ESR1 total body knockout female mice show lower VEGFA in adipose tissue.\",\n      \"method\": \"ChIP for HIF1A binding to VEGFA promoter; siRNA knockdown of ESR1; ESR1 agonist/antagonist treatment in 3T3-L1 cells; ESR1 total body knockout mice\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus siRNA knockdown plus in vivo KO model, single lab\",\n      \"pmids\": [\"29196658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"δEF1 represses ERα transcription by binding to the E2-box on the ERα promoter, an effect induced by E2 via ERα-dependent PI3K or NF-κB pathway; elevated δEF1 reduces ERα levels and confers tamoxifen resistance, while δEF1 depletion restores ERα expression and tamoxifen sensitivity.\",\n      \"method\": \"Luciferase reporter assays with E2-box promoter constructs; ChIP for δEF1 binding; siRNA knockdown; overexpression; western blotting\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter binding by ChIP, siRNA loss-of-function and overexpression with tamoxifen sensitivity readout, single lab\",\n      \"pmids\": [\"23285017\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ESR1/ERα is a ligand-regulated nuclear transcription factor that binds estrogen response elements (EREs) directly or tethers to other transcription factors (e.g., SP1, AP1) at non-ERE sites to regulate target gene expression; its activity is modulated by post-translational modifications including monoubiquitination (required for Ser118 phosphorylation, AKT activation, and proliferation) and polyubiquitination via E3 ligases; somatic gain-of-function mutations in the ligand-binding domain (hotspots Y537S, D538G, etc.) confer ligand-independent constitutive activity, allele-specific neomorphic chromatin recruitment via FOXA1-driven reprogramming, enhanced metastatic adhesion/migration phenotypes, and resistance to aromatase inhibitors and fulvestrant; ERα expression is epigenetically silenced by ZEB1/DNMT3B/HDAC1-mediated promoter hypermethylation; Esr1+ neurons in the lateral hypothalamus signal aversion through projections to the lateral habenula.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ESR1 encodes ERα, a ligand-regulated nuclear transcription factor that controls estrogen-driven gene programs by either binding estrogen response elements (EREs) directly or tethering to other transcription factors at non-ERE sites; in vivo loss of its DNA-binding function shows that a substantial fraction of estradiol-regulated transcripts are governed through tethered, non-ERE mechanisms [#2]. ERα can heterodimerize with ERβ, which restrains ERα-mediated transcription, and both receptors co-cluster in discrete ligand-induced nuclear foci [#0]; both can independently transduce the estradiol proliferative signal in mammary epithelium [#1]. A recurrent mechanistic theme is cooperative DNA binding with SP1: the ligand-dependent ERα–SP1 complex activates the TNFα promoter to drive caspase-3–dependent apoptosis in one context [#4] and the Slc2a4/GLUT4 promoter to promote glucose-transporter expression in adipocytes [#8]. ERα activity is gated by post-translational modification — monoubiquitination is required for E2-induced Ser118 phosphorylation, extranuclear AKT activation, cyclin D1 promoter activation, IGF-1R association, and proliferation [#3]. ESR1 expression is itself epigenetically silenced through a ZEB1/DNMT3B/HDAC1 complex that hypermethylates the ESR1 promoter, and relieving this silencing restores antiestrogen sensitivity [#6]. In metastatic breast cancer, somatic ligand-binding-domain hotspot mutations (Y537S, D538G) confer constitutive ligand-independent activity and endocrine-therapy resistance [#5]; these alleles drive FOXA1-dependent cistrome reprogramming and neomorphic transcriptional programs that remodel cell adhesion and promote metastasis [#7, #12], and additional acquired mutations at residue F404 disrupt fulvestrant pi-stacking to cause selective drug resistance [#16]. Beyond its transcriptional roles, Esr1-expressing neurons in the lateral hypothalamus signal aversion via projections to the lateral habenula [#15].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Established that ERα does not act alone but forms functional heterodimers with ERβ that modulate its transcriptional output and co-organize into defined nuclear chromatin foci.\",\n      \"evidence\": \"Live-cell imaging of GFP-tagged receptors with deletion mutants and colocalization with chromatin-remodeling markers\",\n      \"pmids\": [\"12351687\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous heterodimer occupancy at native target genes not mapped\", \"Mechanism of ERβ inhibition of ERα not resolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Resolved whether ERα and ERβ have distinct roles in estrogen-driven proliferation, showing ERα initiates the proliferative signal while ERβ governs ERα nuclear recycling and responsiveness.\",\n      \"evidence\": \"BrdU incorporation and immunofluorescence in WT and ERβ-knockout mice under multiple ligand conditions\",\n      \"pmids\": [\"14762170\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of ERα nuclear loss/return unknown\", \"Target genes mediating proliferation not identified\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Separated direct ERE-driven transcription from tethered non-ERE regulation in vivo, quantifying that a large fraction of estradiol-regulated genes use DNA-binding-independent mechanisms.\",\n      \"evidence\": \"KIKO DNA-binding-deficient knock-in mouse with genome-wide expression profiling across three genotypes\",\n      \"pmids\": [\"19812388\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of tethering transcription factors at non-ERE sites not enumerated\", \"Tissue specificity beyond uterus unaddressed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined monoubiquitination as a required upstream switch coupling ERα to Ser118 phosphorylation, extranuclear AKT signaling, IGF-1R association, and proliferation.\",\n      \"evidence\": \"Site-directed mutagenesis of ubiquitination sites with signaling, reporter, Co-IP, and proliferation readouts\",\n      \"pmids\": [\"21356307\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase mediating monoubiquitination not identified\", \"Single-lab functional readouts\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrated ERα can cooperate with SP1 to drive a pro-apoptotic transcriptional program, broadening ERα function beyond proliferation.\",\n      \"evidence\": \"Co-IP, TNFα promoter reporter with SP1-site deletions, and SP1-inhibitor treatment in Hep3B cells\",\n      \"pmids\": [\"23733894\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Context-dependence (overexpression in ER-negative cells) limits generalization\", \"Endogenous relevance not shown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified ligand-binding-domain hotspot mutations as the mechanistic basis of acquired endocrine resistance via constitutive ligand-independent ERα activity.\",\n      \"evidence\": \"Mutation characterization across >900 patients with in vitro constitutive-activity assays and xenograft antagonist-sensitivity testing\",\n      \"pmids\": [\"27986707\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Allele-specific downstream programs not yet resolved at this stage\", \"Structural basis of constitutive activity not detailed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established a transcriptional/epigenetic silencing mechanism controlling ESR1 expression itself through a ZEB1/DNMT3B/HDAC1 promoter complex linked to antiestrogen sensitivity.\",\n      \"evidence\": \"ChIP, Co-IP of the repressor complex, siRNA, bisulfite sequencing, and xenograft assays\",\n      \"pmids\": [\"28383555\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream signals activating ZEB1 in this context not defined\", \"Reversibility in patients not tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed mutant ERα acquires neomorphic, allele-specific chromatin recruitment driving pro-metastatic transcription rather than merely mimicking liganded receptor.\",\n      \"evidence\": \"ChIP-seq cistrome mapping and genetic screens across breast cancer models with clinical mutations\",\n      \"pmids\": [\"29438694\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Pioneer factor driving neomorphic recruitment not yet pinpointed in this study\", \"Therapeutic targeting of neomorphic sites unaddressed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Mechanistically linked hotspot mutations to FOXA1-driven cistrome reprogramming that remodels adhesion gene programs to promote circulating tumor cell cluster formation and metastasis.\",\n      \"evidence\": \"Genome-edited mutant models with cistrome/transcriptome profiling, in vivo CTC analysis, and five clinical cohorts\",\n      \"pmids\": [\"35078818\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How FOXA1 is redirected by LBD mutations remains mechanistically incomplete\", \"Generalizability across mutation alleles partially explored\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Extended mutant-ERα reprogramming to ER-binding-independent outputs, including basal cytokeratin induction via a progesterone-receptor-orchestrated insulated neighborhood and paracrine immune mediator changes.\",\n      \"evidence\": \"Genome-edited models with ATAC-seq/ChIP-seq, single-cell RNA-seq, and clinical samples\",\n      \"pmids\": [\"35440136\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal contribution of PR insulated neighborhood to phenotype not isolated\", \"Immune crosstalk consequences for therapy untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined a non-transcription-factor neural role, showing Esr1+ lateral hypothalamic neurons projecting to the lateral habenula encode aversion and a persistent aversive state.\",\n      \"evidence\": \"Patch-seq classification, optogenetic activation, large-scale recordings, and behavioral assays\",\n      \"pmids\": [\"37349481\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ERα transcriptional activity is required for this circuit function not established\", \"Ligand dependence of the neural phenotype unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Resolved a structural determinant of drug binding, identifying ERα F404 as a pi-stacking residue whose mutation selectively abolishes fulvestrant efficacy while sparing oral degraders.\",\n      \"evidence\": \"In silico structural modeling, in vitro single/compound mutant models, and clinical ctDNA sequencing from PlasmaMATCH\",\n      \"pmids\": [\"37982575\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Crystallographic confirmation of the pi-stacking bond not provided\", \"Clinical frequency and prognostic impact of F404 mutations not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ERα PTM codes, cofactor tethering, and mutation-driven cistrome reprogramming are integrated into a unified, predictively targetable mechanism remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model unifying neomorphic chromatin recruitment with LBD mutation\", \"E3 ligases governing ERα ubiquitination states incompletely mapped\", \"Link between transcriptional ERα biology and Esr1+ neuronal function unexplored\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 5, 7, 11]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [2, 11]},\n      {\"term_id\": \"GO:0003700\", \"supporting_discovery_ids\": []}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 1, 11]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 7, 11]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [5, 7, 12, 16]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [6, 7, 13]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ESR2\", \"SP1\", \"FOXA1\", \"IGF-1R\", \"ZEB1\", \"ZNF143\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}